Angle PLC Announces Holding(s) in Company
Tweet
Share
E-mailGet Alerts AGL Hot Sheet
Join SI Premium – FREE
GUILDFORD, SURREY -- (Marketwired) -- 04/04/17 -- Angle PLC (AIM: AGL) (OTCQX: ANPCY)
AIM: AGL; OTCQX: ANPCY
For immediate release 4 April 2017
ANGLE plc ("the Company")
Holding(s) in Company
The Company has been informed by Lombard Odier Investment Managers group ("Lombard") that, following its recent acquisition of Henderson Volantis from Henderson Global plc ("Henderson"), Lombard has acquired ordinary shares in the Company via an in-specie transfer of accounts managed by Henderson on a discretionary basis to Lombard. Further information is set out below.
---------------------
TR-1: NOTIFICATION OF
MAJOR INTEREST IN
SHARES(i)
---------------------
----------------------------------------------------------------------------
1. Identity of the issuer or the underlying
issuer of existing shares to which voting rights ANGLE Plc
are attached: ii
----------------------------------------------------------------------------
2 Reason for the notification (please tick the appropriate box or boxes):
----------------------------------------------------------------------------
An acquisition or disposal of voting rights
----------------------------------------------------------------------------
An acquisition or disposal of qualifying
financial instruments which may result in the
acquisition of shares already issued to which
voting rights are attached
----------------------------------------------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
----------------------------------------------------------------------------
An event changing the breakdown of voting rights
----------------------------------------------------------------------------
Other (please specify): Transfer of accounts
managed on a discretionary basis by Henderson
Group Plc to Lombard Odier Investment Managers X
group
----------------------------------------------------------------------------
Lombard Odier Asset
3. Full name of person(s) subject to the Management (Europe)
notification obligation: iii Limited
----------------------------------------------------------------------------
Disclosure on behalf of
accounts managed on a
4. Full name of shareholder(s) discretionary basis by
(if different from 3.):iv Lombard Odier Investment
Managers group.
----------------------------------------------------------------------------
5. Date of the transaction and date on
which the threshold is crossed or 01/04/2017
reached: v
----------------------------------------------------------------------------
6. Date on which issuer notified: 03/04/2017
----------------------------------------------------------------------------
7. Threshold(s) that is/are crossed or
reached: vi, vii above 5%
----------------------------------------------------------------------------
----------------------------------------------------------------------------
8. Notified details:
----------------------------------------------------------------------------
A: Voting rights attached to sharesviii, ix
----------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the triggering
of to the triggering transaction
shares if transaction
possible
using
the ISIN
CODE
----------------------------------------------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights x
Shares Voting
Rights
--------------------------------------------
Direct Indirect
Direct xi xii Direct Indirect
----------------------------------------------------------------------------
5,899,16
GB0034330679 4 7.88%
----------------------------------------------------------------------------
----------------------------------------------------------------------------
B: Qualifying Financial Instruments
----------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of
instrument datexiii Conversion rights that may voting
Periodxiv be rights
acquired if the
instrument is
exercised/
converted.
----------------------------------------------------------------------------
----------------------------------------------------------------------------
----------------------------------------------------------------------------
C: Financial Instruments with similar economic effect to Qualifying
Financial Instruments xv, xvi
----------------------------------------------------------------------------
Resulting situation after the triggering transaction
----------------------------------------------------------------------------
Type of Exercise Expiration Exercise/ Number of voting % of voting
financial price date xvii Conversion rights rights xix, xx
instrument periodxvii instrument
i refers to
----------------------------------------------------------------------------
Nominal Delta
-----------------
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Total (A+B+C)
----------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
----------------------------------------------------------------------------
5,899,164 7.88%
----------------------------------------------------------------------------
---------------------------------------------------------------------------
9. Chain of controlled undertakings through which the voting rights and/or
the
financial instruments are effectively held, if applicable:xxi
---------------------------------------------------------------------------
---------------------------------------------------------------------------
---------------------------------------------------------------------------
Proxy Voting:
---------------------------------------------------------------------------
10. Name of the proxy holder:
---------------------------------------------------------------------------
11. Number of voting rights proxy holder will cease to hold:
---------------------------------------------------------------------------
12. Date on which proxy holder will cease to hold
voting rights:
---------------------------------------------------------------------------
---------------------------------------------------------------------------
13. Additional information:
---------------------------------------------------------------------------
14. Contact name: Kiran Bassi
---------------------------------------------------------------------------
15. Contact telephone number: +44 20 3206 6000
---------------------------------------------------------------------------
----------------------------------------------------------------------------
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
----------------------------------------------------------------------------
----------------------------------------------------------------------------
1. Identity of the issuer or the underlying
issuer of existing shares to which voting ANGLE Plc
rights are attached:ii
----------------------------------------------------------------------------
2 Reason for the notification (please tick the appropriate box or boxes):
----------------------------------------------------------------------------
An acquisition or disposal of voting rights
----------------------------------------------------------------------------
An acquisition or disposal of qualifying
financial instruments which may result in
the acquisition of shares already issued to
which voting rights are attached
----------------------------------------------------------------------------
An acquisition or disposal of instruments
with similar economic effect to qualifying
financial instruments
----------------------------------------------------------------------------
An event changing the breakdown of voting
rights
----------------------------------------------------------------------------
Other (please specify): In specie transfer
out X
----------------------------------------------------------------------------
3. Full name of person(s) subject to the
notification obligation:iii Henderson Group plc
----------------------------------------------------------------------------
4. Full name of shareholder(s)
(if different from 3.):iv
----------------------------------------------------------------------------
5. Date of the transaction and date on
which the threshold is crossed or 31 March 2017
reached:v
----------------------------------------------------------------------------
6. Date on which issuer notified: 3 April 2017
----------------------------------------------------------------------------
7. Threshold(s) that is/are crossed or
reached:vi, vii Below 5%
----------------------------------------------------------------------------
-----------------------------------------------------------------------------
8. Notified details:
-----------------------------------------------------------------------------
A: Voting rights attached to sharesviii, ix
-----------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the triggering
of to the triggering transaction
shares if transaction
possible
using
the ISIN
CODE
----------------------------------------------------------------
Number Number Number Number of voting % of voting
of of of rights rights x
Shares Voting shares
Rights
------------------------------------------
Direct Indirect
Direct xi xii Direct Indirect
-----------------------------------------------------------------------------
Ordinary 4,205,074 4,205,074 Below 5% Below 5%
GB0034330679
-----------------------------------------------------------------------------
-----------------------------------------------------------------------------
B: Qualifying Financial Instruments
-----------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------
Type of financial Expiration Exercise/ Number of voting % of
instrument datexiii Conversion rights that may voting
Periodxiv be rights
acquired if the
instrument is
exercised/
converted.
-----------------------------------------------------------------------------
-----------------------------------------------------------------------------
-----------------------------------------------------------------------------
C: Financial Instruments with similar economic effect to Qualifying Financial
Instruments xv, xvi
-----------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------
Type of Exercise Expiration Exercise Number of voting % of voting
financial price date xvii / rights rights xix, xx
instrument Conversi instrument
on refers to
periodxv
iii
-----------------------------------------------------------------------------
Nominal Delta
----------------
-----------------------------------------------------------------------------
-----------------------------------------------------------------------------
Total (A+B+C)
-----------------------------------------------------------------------------
Number of voting rights Percentage of voting rights
-----------------------------------------------------------------------------
Below 5% Below 5%
-----------------------------------------------------------------------------
----------------------------------------------------------------------------
9. Chain of controlled undertakings through which the voting rights and/or
the
financial instruments are effectively held, if applicable:xxi
----------------------------------------------------------------------------
See Annex 1 below.
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Proxy Voting:
----------------------------------------------------------------------------
10. Name of the proxy holder:
----------------------------------------------------------------------------
11. Number of voting rights proxy holder will cease to hold:
----------------------------------------------------------------------------
12. Date on which proxy holder will cease to hold voting rights:
----------------------------------------------------------------------------
----------------------------------------------------------------------------
13. Additional information:
----------------------------------------------------------------------------
[email protected]
14. Contact name: om
----------------------------------------------------------------------------
15. Contact telephone number: 020 7818 1818
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Annex 1: Information in relation to the person subject to the notification
obligation (please tick the applicable box):[ ] Person subject to the
notification obligation is not controlled by any natural person or legal
entity and does not control any other undertaking(s) holding directly or
indirectly an interest in the (underlying) issuer.xiii[X] Full chain of
controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entityxiv:
----------------------------------------------------------------------------
% of voting
rights
% of voting through Total of
rights if financial both if it
it equals instruments equals or
Namexv or is if it is higher
higher than equals or than the
the is higher notifiable
notifiable than the threshold
threshold notifiable
threshold
----------------------------------------------------------------------------
Henderson Group plc, Henderson Group
Holdings Asset Management Limited, HGI
Asset Management Group Limited,
Henderson Global Group Limited,
Henderson Holdings Group Limited, HGI Below 5% - Below 5%
Group Limited, Henderson Global
Investors (Holdings) Limited, AlphaGen
Capital Limited
----------------------------------------------------------------------------
----------------------------------------------------------------------------
Henderson Group plc, Henderson Group
Holdings Asset Management Limited, HGI
Asset Management Group Limited,
Henderson Global Group Limited,
Henderson Holdings Group Limited, HGI Below 5% - Below 5%
Group Limited, Henderson Global
Investors (Holdings) Limited, Henderson
Global Investors Limited
----------------------------------------------------------------------------
For further information:
ANGLE plc 01483 685830 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Cenkos Securities 020 7397 8900 Stephen Keys (Nominated adviser), Steve Cox Russell Kerr (Sales) WG Partners 020 3705 9330 David Wilson Claes Spång FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert 020 3727 1000 Kimberly Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com ANGLE is a specialist medtech company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.
ANGLE's cell separation technology is called the Parsortix" system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix has a CE Mark for Europe and FDA authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.
As well as cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future.
ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit: www.angleplc.com
This information is provided by RNS The company news service from the London Stock Exchange
Contacts: RNS Customer Services 0044-207797-4400 [email protected] http://www.rns.com
Source: Angle PLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vivos Therapeutics opens sleep center in Henderson, Nevada
- Questor Technology Signs Letter of Intent to Acquire Emission Rx in Strategic Move to Lead North American Emissions Combustion Technology
- AeroVironment to Establish Industrial Presence in Greece Through AV Eagle
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Henderson Group, Definitive Agreement, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
